Myriad RBM Inks Deal with Bio-Rad to Develop and Sell Immunoassay Kits | GenomeWeb

Myriad RBM and Bio-Rad Laboratories said this week that they are partnering to develop and distribute immunoassay kits.

The deal gives Bio-Rad exclusive distribution rights, for research purposes, to Myriad RBM's catalog of quantitative multiplexed immunoassays to run on Bio-Rad's Bio-Plex 200, Bio-Plex 3D, and Bio-Plex MagPix instruments.

According to Sam LaBrie, vice president of corporate development at Myriad RBM, the agreement provides Myriad RBM with access to Bio-Rad's customer base – much of which Myriad RBM has not traditionally targeted.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.